DNA methyltransferase inhibitors in myelodysplastic syndrome

Best Practice and Research: Clinical Haematology

Volumn 17, Issue 4 SPEC.ISS., 2004, Pages 585-594

  Silverman, Lewis R ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

Azacitidine; DNA methyl transferase inhibitors; Myelodysplastic syndrome

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; AMIFOSTINE; ARYLBUTYRIC ACID DERIVATIVE; AZACITIDINE; BRYOSTATIN 1; BUTYRIC ACID DERIVATIVE; CYTARABINE; CYTOKINE; DNA; DNA METHYLTRANSFERASE; GEMCITABINE; HEME ARGINATE; HEXAMETHYLENEBISACETAMIDE; HOMOHARRINGTONINE; METHYLTRANSFERASE INHIBITOR; NUCLEOSIDE ANALOG; RETINOID; RETINOL; TUMOR SUPPRESSOR PROTEIN; VITAMIN D;

ACUTE GRANULOCYTIC LEUKEMIA; ALLOGENIC BONE MARROW TRANSPLANTATION; ARTHRALGIA; AUTOLOGOUS BONE MARROW TRANSPLANTATION; BLOOD TRANSFUSION; BONE MARROW BIOPSY; BONE MARROW CELL; BONE MARROW SUPPRESSION; BONE MARROW TRANSPLANTATION; CANCER SURVIVAL; CELL DIFFERENTIATION; CELL GROWTH; CELL MATURATION; CHROMOSOME ABERRATION; CLINICAL PROTOCOL; CLINICAL TRIAL; COMORBIDITY; CYTOKINE RELEASE; DIARRHEA; DNA METHYLATION; DNA SEQUENCE; DROWSINESS; DRUG EFFICACY; DRUG SAFETY; ELDERLY CARE; FATIGUE; GENE SILENCING; GENETIC TRANSCRIPTION; HEMATOPOIESIS; HUMAN; IMMUNOLOGY; INHIBITION KINETICS; LEUKOPENIA; MALIGNANT TRANSFORMATION; MEDICAL DECISION MAKING; META ANALYSIS; MYELODYSPLASTIC SYNDROME; NAUSEA AND VOMITING; PATHOPHYSIOLOGY; PATIENT CARE; PNEUMONIA; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; RISK ASSESSMENT; SIGNAL TRANSDUCTION; SYSTEMATIC REVIEW; THROMBOCYTE TRANSFUSION; THROMBOCYTOPENIA; TREATMENT OUTCOME;

EID: 5744248237     PISSN: 15216926     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.beha.2004.08.010     Document Type: Review

References (42)

1. L.R. Silverman J.F. Holland R.S. Weinberg et al. Effects of treatment with 5-azacytidine on the in vivo and in vitro hematopoiesis in patients with myelodysplastic syndromes Leukemia 7 supplement 1 1993 21-29
2. L. Silverman J.F. Holland E. Frei et al. The myelodysplastic syndrome in: J.F. Holland E. Frei eds. Cancer Medicine 2000 Decker Inc. Hamilton, Ontario 1931-1946
3. M.L. Heaney D.W. Golde Myelodysplasia The New England Journal of Medicine 340 1999 1649-1660
4. C. Aul U. Germing N. Gattermann H. Minning Increasing incidence of myelodysplastic syndromes: real or fictitious? Leukemia Research 22 1998 93-100
5. V. Santini P.R. Ferrini Differentiation therapy of myelodysplastic syndromes: fact or fiction? British Journal of Haematology 102 1998 1124-1138
6. S.D. Gore L.J. Weng S. Zhai et al. Impact of the putative differentiating agent sodium phenylbutyrate on myelodysplastic syndromes and acute myeloid leukemia Clinical Cancer Research 7 2001 2330-2339
7. T. Nosslinger R. Reisner E. Koller et al. Myelodysplastic syndromes, from French-American-British to World Health Organization: comparison of classifications on 431 unselected patients from a single institution Blood 98 2001 2935-2941
8. C. Aul A. Giagounidis U. Germing A. Ganser Evaluating the prognosis of patients with myelodysplastic syndromes Annals of Hematology 81 2002 485-497
9. G.F. Sanz M.A. Sanz P.L. Greenberg Prognostic factors and scoring systems in myelodysplastic syndromes Haematologica 83 1998 358-368
10. P.L. Greenberg Apoptosis and its role in the myelodysplastic syndromes: implications for disease natural history and treatment Leukemia Research 22 1998 1123-1136
11. K.D. Robertson P.A. Jones DNA methylation: past, present and future directions Carcinogenesis 21 2000 461-467
12. R. Singal G.D. Ginder DNA methylation Blood 93 1999 4059-4070
13. M. Kizaki H.P. Koeffler Differentiation-inducing agents in the treatment of myelodysplastic syndromes Seminars in Oncology 19 1992 95-105
14. S.X. Guo T. Taki H. Ohnishi et al. Hypermethylation of p16 and p15 genes and RB protein expression in acute leukemia Leukemia Research 24 2000 39-46
15. T. Uchida T. Kinoshita H. Nagai et al. Hypermethylation of the p15INK4B gene in myelodysplastic syndromes Blood 90 1997 1403-1409
16. B. Quesnel P. Fenaux P15INK4b gene methylation and myelodysplastic syndromes Leukemia and Lymphoma 35 1999 437-443
17. N.J. Farinha S. Shaker M. Lemaire et al. Re-expression of p15, p73 and E-Cadherin in leukemic cells after treatment with different concentrations of 5-aza-2′deoxycytidine, an inhibitor of DNA methylation Blood 100 2002 322a (abstract)
18. R.L. Momparler Molecular, cellular and animal pharmacology of 5-aza-2′-deoxycytidine Pharmacology and Therapeutics 30 1985 287-299
19. A. Pinto V. Attadia A. Fusco et al. 5-Aza-2′-deoxycytidine induces terminal differentiation of leukemic blasts from patients with acute myeloid leukemias Blood 64 1984 922-929
20. M. Lubbert DNA methylation inhibitors in the treatment of leukemias, myelodysplastic syndromes and hemoglobinopathies: clinical results and possible mechanisms of action Current Topics in Microbiology and Immunology 249 2000 135-164
21. L. Silverman J.F. Holland E.P. Demakos Azacytidine (azaC) in myelodysplastic syndromes (MDS)CALGB 8421 and 8921 Annals of Hematology 68 1994 12 (abstract)
22. L.R. Silverman Targeting hypomethylation of DNA to achieve cellular differentiation in myelodysplastic syndromes (MDS) Oncologist 6 supplement 5 2001 8-14
23. C.R. Chitambar J.A. Libnoch W.G. Matthaeus et al. Evaluation of continuous infusion low-dose 5-azacytidine in the treatment of myelodysplastic syndromes American Journal of Hematology 37 1991 100-104
24. H. Rugo L. Damon C. Ries C. Linder Compassionate use of subcutaneous 5-azacytidine (Aza C) in the treatment of myelodysplastic syndromes (MDS) Leukemia Research 23 1999 S72-S75
25. M.C. Petti F. Mandelli V. Zagonel et al. Pilot study of 5-aza-2′-deoxycytidine (Decitabine) in the treatment of poor prognosis acute myelogenous leukemia patients: preliminary results Leukemia 7 supplement 1 1993 36-41
26. V. Zagonel R.G. Lo G. Marotta et al. 5-Aza-2′-deoxycytidine (Decitabine) induces trilineage response in unfavourable myelodysplastic syndromes Leukemia 7 supplement 1 1993 30-35
27. P. Wijermans J.W. Krulder P.C. Huijgens P. Neve Continuous infusion of low-dose 5-Aza-2′-deoxycytidine in elderly patients with high-risk myelodysplastic syndrome Leukemia 11 1997 1-5
28. P. Wijermans M. Lubbert G. Verhoef et al. Low-dose 5-aza-2′-deoxycytidine, a DNA hypomethylating agent, for the treatment of high-risk myelodysplastic syndrome: a multicenter phase II study in elderly patients Journal of Clinical Oncology 18 2000 956-962
29. L.R. Silverman E.P. Demakos B.L. Peterson et al. Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B Journal of Clinical Oncology 20 2002 2429-2440
30. A.B. Kornblith J.E. Herndon L.R. Silverman et al. Impact of azacytidine on the quality of life of patients with myelodysplastic syndrome treated in a randomized phase III trial: a Cancer and Leukemia Group B study Journal of Clinical Oncology 20 2002 2441-2452
31. J. Gryn Z.R. Zeigler R.K. Shadduck et al. Treatment of myelodysplastic syndromes with 5-azacytidine Leukemia Research 26 2002 893-897
32. E.E. Cameron K.E. Bachman S. Myohanen et al. Synergy of demethylation and histone deacetylase inhibition in the re- expression of genes silenced in cancer Nature Genetics 21 1999 103-107
33. L. Camacho H.J. Ryan S. Chanel et al. Transcription modulation, a pilot study of sodium phenylbutyrate plus 5-azacytidine Blood 98 2001 460a (abstract)
34. C.B. Miller J.G. Herman S.B. Baylin et al. Phase I dose-descalation trial of combined DNA methyltransferase (MeT/histone deacetylase (HDAC) inhibition in myeloid malignancies Blood 98 2001 622a (abstract)
35. X. Lopez-Karpovitch O. Barrales-Benitez M. Flores J. Piedras Effect of azacytidine in the release of leukemia inhibitory factor, oncostatin m, interleukin (IL)-6, and IL-11 by mononuclear cells of patients with refractory anemia Cytokine 20 2002 154-162
36. S. Zinzar L.R. Silverman E.B. Richardson et al. Azacytidine plus verapamil induces the differentiation of a newly characterized biphenotypic human myeloid-B lymphoid leukemic cell line BW-90 Leukemia Research 22 1998 677-685
37. M. Andreeff R. Stone J. Michaeli et al. Hexamethylene bisacetamide in myelodysplastic syndrome and acute myelogenous leukemia: a phase II clinical trial with a differentiation- inducing agent Blood 80 1992 2604-2609
38. E.J. Feldman K.P. Seiter T. Ahmed et al. Homoharringtonine in patients with myelodysplastic syndrome (MDS) and MDS evolving to acute myeloid leukemia Leukemia 10 1996 40-42
39. A.F. List F. Brasfield R. Heaton et al. Stimulation of hematopoiesis by amifostine in patients with myelodysplastic syndrome Blood 90 1997 3364-3369
40. L. Volin T. Ruutu S. Knuutila R. Tenhunen Heme arginate treatment for myelodysplastic syndromes Leukemia Research 12 1988 423-431
41. R.M. Stone Bryostatin 1: differentiating agent from the depths Leukemia Research 21 1997 399-401
42. P. Wijermans G. Verhoef M. Lubbert Decitabine in elderly patients with high risk MDS: an update Blood 100 2002 96a (abstract)